Filing Details

Accession Number:
0001209191-17-041629
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-23 16:02:58
Reporting Period:
2017-06-22
Filing Date:
2017-06-23
Accepted Time:
2017-06-23 16:02:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
816284 Celgene Corp CELG Pharmaceutical Preparations (2834) 222711928
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1232505 J Robert Hugin C/o Celgene Corporation
86 Morris Avenue
Summit NJ 07901
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-22 60,000 $29.26 1,033,909 No 4 M Direct
Common Stock Disposition 2017-06-22 60,000 $134.14 973,909 No 4 S Direct
Common Stock Acquisiton 2017-06-22 60,000 $33.78 1,033,909 No 4 M Direct
Common Stock Disposition 2017-06-22 60,000 $134.14 973,909 No 4 S Direct
Common Stock Acquisiton 2017-06-22 55,970 $24.81 1,029,879 No 4 M Direct
Common Stock Disposition 2017-06-22 55,970 $134.14 973,909 No 4 S Direct
Common Stock Acquisiton 2017-06-22 2,750 $36.36 976,659 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-06-22 60,000 $0.00 60,000 $29.27
Common Stock Stock Option (right to buy) Disposition 2017-06-22 60,000 $0.00 60,000 $36.78
Common Stock Stock Option (right to buy) Disposition 2017-06-22 55,970 $0.00 55,970 $24.81
Common Stock Stock Option (right to buy) Disposition 2017-06-22 2,750 $0.00 2,750 $36.36
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-07-10 No 4 M Direct
0 2017-10-09 No 4 M Direct
0 2018-01-08 No 4 M Direct
0 2022-01-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,600 Indirect By Children
Common Stock 641 Indirect 401(K) Plan
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $134.00 to $135.13, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. The option was fully exercisable.
  4. The option was issued pursuant to the Company's 1998 Employee Stock Option Plan.
  5. The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015)).